ArticleGut microbes2023
Multimodal metagenomic analysis reveals microbial single nucleotide variants as superior biomarkers for early detection of colorectal cancer.
Article in Gut microbes, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 30 citations in OpenAlex.
- Gut Microbial Topology and Metabolic Signatures Associated With Colorectal Neoplasia.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Review
- Multi-omics and artificial intelligence for precision drug discovery and potential clinical applications.Signal transduction and targeted therapy · 2026Review
- Gut microbiome in colorectal cancer: recent advances and clinical implications.Annals of coloproctology · 2026Review
- Integrative multi-omics reveals microbial genomic variants driving altered host-microbe interactions in autism spectrum disorder.Cell reports. Medicine · 2026Article
- Role of the Plant-Microbiome Partnership in Environmentally Harmonious 21st Century Agriculture.Microorganisms · 2025Review
- Can Salivary Biomarkers Serve as Diagnostic and Prognostic Tools for Early Detection in Patients with Colorectal Cancer? A Systematic Review.Current issues in molecular biology · 2025Review
- Multi-kingdom microbial changes and their associations with the clinical characteristics in schizophrenia patients.Translational psychiatry · 2025Article
- Intestinal dysbiosis and colorectal cancer.Chinese medical journal · 2025Review
- Huangqin decoction inhibits colorectal inflammatory cancer transformation by improving gut microbiome-mediated metabolic dysfunction.Journal of pharmaceutical analysis · 2025Article
- Regulating Intratumoral Fungi With Hydrogels: A Novel Approach to Modulating the Tumor Microbiome for Cancer Therapy.Cancer medicine · 2025Review
- Gut microbiome in colorectal cancer: metagenomics from bench to bedside.JNCI cancer spectrum · 2025Review
- Predicting immune status and gene mutations in stomach adenocarcinoma patients based on inflammatory response-related prognostic features.Discover oncology · 2025Article
- Distinct Effects ofMicroorganisms · 2025Article
- Stage-specific fecal and salivary microbiota signatures for noninvasive detection of colorectal cancer.Frontiers in microbiology · 2025Article
- Identification and validation of microbial biomarkers from cross-cohort datasets using xMarkerFinder.Nature protocols · 2024Review
- Application ofWorld journal of gastrointestinal oncology · 2024Article
- Co-evolution of vaginal microbiome and cervical cancer.Journal of translational medicine · 2024Article
- Article
- Multi-kingdom microbial signatures in excess body weight colorectal cancer based on global metagenomic analysis.Communications biology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microbial signatures show remarkable potentials in predicting colorectal cancer (CRC). This study aimed to evaluate the diagnostic powers of multimodal microbial signatures, multi-kingdom species, genes, and single-nucleotide variants (SNVs) for detecting precancerous adenomas. We performed cross-cohort analyses on whole metagenome sequencing data of 750 samples via xMarkerFinder to identify adenoma-associated microbial multimodal signatures. Our data revealed that fungal species outperformed species from other kingdoms with an area under the ROC curve (AUC) of 0.71 in distinguishing adenomas from controls. The microbial SNVs, including dark SNVs with synonymous mutations, displayed the strongest diagnostic capability with an AUC value of 0.89, sensitivity of 0.79, specificity of 0.85, and Matthews correlation coefficient (MCC) of 0.74. SNV biomarkers also exhibited outstanding performances in three independent validation cohorts (AUCs = 0.83, 0.82, 0.76; sensitivity = 1.0, 0.72, 0.93; specificity = 0.67, 0.81, 0.67, MCCs = 0.69, 0.83, 0.72) with high disease specificity for adenoma. In further support of the above results, functional analyses revealed more frequent inter-kingdom associations between bacteria and fungi, and abnormalities in quorum sensing, purine and butanoate metabolism in adenoma, which were validated in a newly recruited cohort via qRT-PCR. Therefore, these data extend our understanding of adenoma-associated multimodal alterations in the gut microbiome and provide a rationale of microbial SNVs for the early detection of CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.